Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Josep M. Llovet, Jiamei Yang et al.|The Lancet Oncology|2015Cited by 1.1k
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trialRoser Pinyol, Josep M. Llovet, Robert Montal et al.|Gut|2018Cited by 338